R&D | May 23, 2026
WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Subscribe To Our Newsletter & Stay Updated
